EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Prof Dirk Müller-Wieland considers the combined effects of diabetes and elevated triglycerides on CV events in primary and secondary prevention populations, the mechanisms that make triglyceride-lowering treatments like EPA effective on a background of diabetes and the current guideline recommendations on their use.
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid (EPA), including the latest sub-analysis of the REDUCE-IT trial, which analysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type 2 diabetes. For context, we reassess the role of diabetes in CV risk and the modifying effect of triglycerides in the diabetic population; we also consider the pleiotropic mechanisms that appear to make EPA an effective treatment in the diabetic state.
This programme is supported by an unrestricted educational grant from Amarin.
Educational Objective
- To provide an update and expert perspectives on recent clinical data from the REDUCE-IT trial, meta-analysis and systematic reviews on novel data with icosapent-ethyl.
Target Audience
- Cardiologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
Diabetes in CV Disease and the Role of Triglycerides
Prof Dirk Müller-Wieland considers the combined effects of diabetes and elevated triglycerides on CV events in primary and secondary prevention populations, the mechanisms that make triglyceride-lowering treatments like EPA effective on a background of diabetes and the current guideline recommendations on their use.
Part 2
Efficacy of Icosapent Ethyl Across the Spectrum of Baseline Triglyceride Glucose Indices
Dr Rahul Aggarwal provides context to the present post-hoc analysis of REDUCE-IT, which looked at the impact of TyG indices on CV risk and whether IPE was effective at reducing risk across baseline TyG tertiles. He then summarises the findings from the late breaking abstract that was presented at EASD and interprets the impact on future practice.
Faculty Biographies
Dirk Müller-Wieland
Professor of Endocrinology, Metabolism and Diabetes
Prof Dirk Müller-Wieland is a specialist in endocrinology and diabetology at University Hospital Aachen, Department of Medical Sciences (Aachen, DE). He leads the Cardiometric Prevention Working Group and the Clinical Study Center. His research and clinical interests focus on gene regulation, lipid metabolism, fat distribution, insulin resistance and cardiovascular risk.
He studied medicine in Germany before completing a two-year research fellowship at the Joslin Diabetes Center, Harvard Medical School, Boston. He later held the Chair of Clinical Biochemistry and Pathobiochemistry at Heinrich Heine University Düsseldorf. From 2006 to 2015, he served as Head of the Department of General Internal Medicine, Gastroenterology, Endocrinology, Diabetes and Metabolism at Asklepios Klinik St. Georg, Hamburg, where he also became founding dean of the Asklepios Medical School.
A key contributor to diabetes research and education, Professor Müller-Wieland was President…